Literature DB >> 21883100

Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer's disease in younger and older age cohorts.

Ben Schmand1, Piet Eikelenboom, Willem A van Gool.   

Abstract

OBJECTIVES: To examine the influence of age on the value of four techniques for diagnosing Alzheimer's disease (AD).
DESIGN: Observational cohort study.
SETTING: Alzheimer's Disease Neuroimaging Initiative. PARTICIPANTS: Individuals with mild cognitive impairment (MCI; n = 179), individuals with AD (n = 91), and normal controls (n = 105). MEASUREMENTS: Neuropsychological tests, structural magnetic resonance imaging (MRI), amyloid-beta and tau in cerebrospinal fluid (CSF), and [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) for the diagnosis of MCI or AD. MCI was defined according to subjective memory complaints corroborated by an informant and an abnormal score on the delayed paragraph recall subtest of the Wechsler Memory Scale-Revised, a Mini-Mental State Examination score greater than 23, and a Clinical Dementia Rating score of 0.5. Participants with AD satisfied National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association criteria of probable AD.
RESULTS: Neuropsychological tests and MRI were the most informative techniques, with 84% and 82% correct classifications, respectively, and areas under the receiver operating characteristic curve (AUCs) of 0.93 (90% confidence interval (CI) = 0.91-0.95) and 0.88 (90% CI = 0.85-0.91). FDG-PET and CSF assessments had 76% and 73% correct classifications, respectively, (AUC = 0.77, 90% CI = 0.71-0.83; AUC = 0.77, 90% CI = 0.73-0.82). These figures increased slightly when the techniques were combined. All analyses were repeated for the younger (<75) and older (≥ 75) halves of the sample. FDG-PET and CSF assessment were substantially less informative in the older cohort, and they did not add diagnostic information when all techniques were combined.
CONCLUSIONS: Structural MRI and neuropsychological assessment are diagnostic methods of first choice if AD is suspected. CSF and FDG-PET add little to these diagnostic techniques, especially in older adults.
© 2011, Copyright the Authors. Journal compilation © 2011, The American Geriatrics Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21883100     DOI: 10.1111/j.1532-5415.2011.03539.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  16 in total

Review 1.  2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Jesse Cedarbaum; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Johan Luthman; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie Shaw; Li Shen; Adam Schwarz; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2015-06       Impact factor: 21.566

2.  Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset.

Authors:  Daniele Altomare; Clarissa Ferrari; Anna Caroli; Samantha Galluzzi; Annapaola Prestia; Wiesje M van der Flier; Rik Ossenkoppele; Bart Van Berckel; Frederik Barkhof; Charlotte E Teunissen; Anders Wall; Stephen F Carter; Michael Schöll; I L Han Choo; Timo Grimmer; Alberto Redolfi; Agneta Nordberg; Philip Scheltens; Alexander Drzezga; Giovanni B Frisoni
Journal:  J Neurol       Date:  2019-07-02       Impact factor: 4.849

3.  Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature.

Authors:  Wei Tang; Qiong Huang; Yu-You Yao; Yan Wang; Yi-Le Wu; Zheng-Yu Wang
Journal:  J Neural Transm (Vienna)       Date:  2014-05-10       Impact factor: 3.575

Review 4.  The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Li Shen; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2013-08-07       Impact factor: 21.566

Review 5.  Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.

Authors:  Catherine Randall; Lisa Mosconi; Mony de Leon; Lidia Glodzik
Journal:  Front Biosci (Landmark Ed)       Date:  2013-06-01

6.  MRI and cerebrospinal fluid biomarkers for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: a diagnostic accuracy study.

Authors:  Edo Richard; Ben A Schmand; Piet Eikelenboom; Willem A Van Gool
Journal:  BMJ Open       Date:  2013-06-20       Impact factor: 2.692

7.  Measuring emotion recognition: Added value in diagnosing dementia of the Alzheimer's disease type.

Authors:  Fijanne Strijkert; Rients Bauke Huitema; Jacoba Margje Spikman
Journal:  J Neuropsychol       Date:  2021-10-18       Impact factor: 2.276

8.  Clinical applicability and cutoff values for an unstructured neuropsychological assessment protocol for older adults with low formal education.

Authors:  Jonas Jardim de Paula; Laiss Bertola; Rafaela Teixeira Ávila; Lafaiete Moreira; Gabriel Coutinho; Edgar Nunes de Moraes; Maria Aparecida Camargos Bicalho; Rodrigo Nicolato; Breno Satler Diniz; Leandro Fernandes Malloy-Diniz
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

9.  Plasma microRNA biomarkers for detection of mild cognitive impairment.

Authors:  Kira S Sheinerman; Vladimir G Tsivinsky; Fiona Crawford; Michael J Mullan; Laila Abdullah; Samuil R Umansky
Journal:  Aging (Albany NY)       Date:  2012-09       Impact factor: 5.682

Review 10.  Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease.

Authors:  Benoît Leclerc; Abedelnasser Abulrob
Journal:  ScientificWorldJournal       Date:  2013-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.